Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis

American Journal of Medicine

Volumn 121, Issue 1, 2008, Pages 43-49

  Berger, Jeffrey S ^a   Brown, David L ^b   Becker, Richard C ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

All cause mortality; Aspirin; Dose; Meta analysis; Myocardial infarction; Secondary prevention; Stable angina; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; PLACEBO;

ANGINA PECTORIS; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG MEGADOSE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

ASPIRIN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MULTICENTER STUDIES AS TOPIC; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 37649002657     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.10.002     Document Type: Article

References (33)

1. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 68 (1991) 28B-35B
2. Fuster V., Stein B., Ambrose J.A., et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 82 3 Suppl (1990) II47-II59
3. Gawaz M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 (2005) 3378-3384
4. Steinhubl S.R., and Moliterno D.J. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 5 (2005) 399-408
5. Wagner D.D., and Burger P.C. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23 (2003) 2131-2137
6. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. [see comment] [erratum appears in BMJ. 1994;308:1540]. BMJ 308 (1994) 81-106
7. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [see comment] [erratum appears in BMJ. 2002;324:141]. BMJ 324 (2002) 71-86
8. Jackson S.P., and Schoenwaelder S.M. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2 (2003) 775-789
9. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25 (2004) 166-181
10. Stein B., Fuster V., Israel D.H., et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 14 (1989) 813-836
11. Tendera M., and Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res 110 (2003) 355-359
12. Patrono C., Coller B., FitzGerald G.A., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 234S-264S
13. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. [erratum appears in Circulation. 2006;113:e847]. Circulation 113 (2006) 2363-2372
14. Meade M.O., and Richardson W.S. Selecting and appraising studies for a systematic review. Ann Intern Med 127 (1997) 531-537
15. Schulz K.F., Chalmers I., Hayes R.J., and Altman D.G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. [see comment]. JAMA 273 (1995) 408-412
16. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. [see comment]. J Neurol Sci 143 (1996) 1-13
17. Farrell B., Godwin J., Richards S., and Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
18. anonymous. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. [see comment]. Lancet 338 (1991) 1345-1349
19. Boysen G., Sorensen P.S., Juhler M., et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 19 (1988) 1211-1215
20. Elwood P.C., Cochrane A.L., Burr M.L., et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1 (1974) 436-440
21. Juul-Moller S., Edvardsson N., Jahnmatz B., et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 340 (1992) 1421-1425
22. Ajani U.A., Ford E.S., Greenland K.J., et al. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 30 (2006) 74-77
23. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
24. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. [see comment] [erratum appears in Lancet. 2005;366:1358]. Lancet 366 (2005) 1267-1278
25. Dagenais G.R., Pogue J., Fox K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. [see comment]. Lancet 368 (2006) 581-588
26. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
27. Rao S.V., Jollis J.G., Harrington R.A., et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. [see comment]. JAMA 292 (2004) 1555-1562
28. Patrono C., Ciabattoni G., Patrignani P., et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72 (1985) 1177-1184
29. Roth G.J., Stanford N., and Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 72 (1975) 3073-3076
30. Mason P.J., Jacobs A.K., and Freedman J.E. Aspirin resistance and atherothrombotic disease. [see comment]. J Am Coll Cardiol 46 (2005) 986-993
31. Pamukcu B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis 23 (2007) 213-222
32. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115 (2007) 3156-3164
33. Campbell C.L., Smyth S., Montalescot G., and Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 (2007) 2018-2024